TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00543725
First received: October 11, 2007
Last updated: March 3, 2016
Last verified: March 2016
Results First Received: June 14, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
HIV-1
Interventions: Drug: TMC278
Drug: efavirenz

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjects

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
680 participants were randomized (340 in TMC 278 and 340 in efavirenz) but only 338 participants were treated with efavirenz (2 were randomized but not treated).

Reporting Groups
  Description
TMC278 25 mg tablet once daily
Efavirenz 600 mg once daily

Participant Flow:   Overall Study
    TMC278     Efavirenz  
STARTED     340     338  
COMPLETED     272     264  
NOT COMPLETED     68     74  
Adverse Event                 18                 27  
Sponsor's Decision                 0                 1  
Subject Non-Compliant                 4                 4  
Subject Ineligible To Continue The Trial                 2                 0  
Subject Reached A Virologic Endpoint                 22                 14  
Protocol Violation                 0                 1  
Withdrawal by Subject                 4                 13  
Lost to Follow-up                 15                 11  
Not specified                 3                 3  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
TMC278 25 mg tablet once daily
Efavirenz 600 mg once daily
Total Total of all reporting groups

Baseline Measures
    TMC278     Efavirenz     Total  
Number of Participants  
[units: participants]
  340     338     678  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     339     337     676  
>=65 years     1     1     2  
Age  
[units: years]
Mean (Standard Deviation)
  36.7  (9.39)     36.4  (8.92)     36.5  (9.15)  
Gender  
[units: participants]
     
Female     90     94     184  
Male     250     244     494  
Region Enroll  
[units: participants]
     
Africa     19     38     57  
Asia     59     61     120  
Latin America     90     85     175  
USA, Canada, Europe, Australia     172     154     326  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48   [ Time Frame: Week 48 ]

2.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 48   [ Time Frame: Week 48 ]

3.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 96   [ Time Frame: Week 96 ]

4.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies Per mL) at Week 96   [ Time Frame: Week 96 ]

5.  Secondary:   Number of Participants With Virological Response (Observed, <50 Copies/mL) at Last On-Treatment Visit (Post-Week 96).   [ Time Frame: Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz ]

6.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 48   [ Time Frame: Week 48 ]

7.  Secondary:   Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 96   [ Time Frame: Week 96 ]

8.  Secondary:   Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)   [ Time Frame: Baseline, Week 48, and Week 96 ]

9.  Secondary:   Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure   [ Time Frame: Week 96 ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame Up to 164 weeks for participants in the TMC278 treatment group and up to 144 weeks for participants in the efavirenz treatment group.
Additional Description Only participants who had at least one of the treatment-emergent adverse events (TEAEs) listed in the Other (non Serious) adverse event (AE) table are included in the total number of participants with Non-Serious AEs.

Frequency Threshold
Threshold above which other adverse events are reported   5  

Reporting Groups
  Description
TMC278 25 mg tablet once daily
Efavirenz 600 mg once daily

Other Adverse Events
    TMC278     Efavirenz  
Total, other (not including serious) adverse events      
# participants affected / at risk     253/340 (74.41%)     259/338 (76.63%)  
Gastrointestinal disorders      
Nausea * 1    
# participants affected / at risk     57/340 (16.76%)     67/338 (19.82%)  
Diarrhoea * 1    
# participants affected / at risk     49/340 (14.41%)     53/338 (15.68%)  
Vomiting * 1    
# participants affected / at risk     22/340 (6.47%)     26/338 (7.69%)  
General disorders      
Fatigue * 1    
# participants affected / at risk     20/340 (5.88%)     29/338 (8.58%)  
Pyrexia * 1    
# participants affected / at risk     15/340 (4.41%)     17/338 (5.03%)  
Infections and infestations      
Nasopharyngitis * 1    
# participants affected / at risk     50/340 (14.71%)     47/338 (13.91%)  
Upper respiratory tract infection * 1    
# participants affected / at risk     43/340 (12.65%)     37/338 (10.95%)  
Bronchitis * 1    
# participants affected / at risk     31/340 (9.12%)     6/338 (1.78%)  
Influenza * 1    
# participants affected / at risk     32/340 (9.41%)     30/338 (8.88%)  
Pharyngitis * 1    
# participants affected / at risk     20/340 (5.88%)     14/338 (4.14%)  
Anogenital warts * 1    
# participants affected / at risk     17/340 (5.00%)     14/338 (4.14%)  
Sinusitis * 1    
# participants affected / at risk     17/340 (5.00%)     19/338 (5.62%)  
Musculoskeletal and connective tissue disorders      
Back pain * 1    
# participants affected / at risk     16/340 (4.71%)     30/338 (8.88%)  
Arthralgia * 1    
# participants affected / at risk     10/340 (2.94%)     17/338 (5.03%)  
Nervous system disorders      
Headache * 1    
# participants affected / at risk     61/340 (17.94%)     53/338 (15.68%)  
Dizziness * 1    
# participants affected / at risk     42/340 (12.35%)     111/338 (32.84%)  
Somnolence * 1    
# participants affected / at risk     17/340 (5.00%)     28/338 (8.28%)  
Psychiatric disorders      
Insomnia * 1    
# participants affected / at risk     38/340 (11.18%)     21/338 (6.21%)  
Abnormal dreams * 1    
# participants affected / at risk     19/340 (5.59%)     26/338 (7.69%)  
Depression * 1    
# participants affected / at risk     24/340 (7.06%)     19/338 (5.62%)  
Respiratory, thoracic and mediastinal disorders      
Cough * 1    
# participants affected / at risk     33/340 (9.71%)     15/338 (4.44%)  
Pharyngolaryngeal pain * 1    
# participants affected / at risk     19/340 (5.59%)     6/338 (1.78%)  
Skin and subcutaneous tissue disorders      
Rash * 1    
# participants affected / at risk     15/340 (4.41%)     49/338 (14.50%)  
Pruritus * 1    
# participants affected / at risk     15/340 (4.41%)     17/338 (5.03%)  
Vascular disorders      
Hypertension * 1    
# participants affected / at risk     23/340 (6.76%)     12/338 (3.55%)  
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA 11.0



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information